SBIR/STTR Research Award

MULTIFUNCTIONAL DRUG-DELIVERY STENT WITH NANOPOROUS COAT

Award identifier 7ad95d1eb9be3b2eede8845a5d1e0444d86a0c7f0eb02f9786d860b8abaa9bd3Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$199,999

Program and phase

SBIR · Phase I

Award year

2010

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
ARAVASC, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
C5QVPEJYM4K8
Solicitation number
PHS2010-1
Topic code
NCI

Research abstract

The overall long-term objective of this proposal is to develop a loco-regional multi-functional theranostic delivery system (MTDS) to treat lung cancer in patients with focal disease, as an adjunct to systemic therapy. The proposed MTDS, releases a clinically proven, cocktail of cancer chemotherapeutic drugs and a fluorescent dye. The cocktail is loaded on a tracheo-bronchial nitinol stent with a nano-porous, radio-opaque, Tantalum coat. It has multiple modes of action. The physical platform in addition to being radio-opaque, props open any obstruction, the combination drugs treat the cancer and the fluorescent dye lights up the tumor to allowing visualization and monitoring of the treatment. The MTDS is predicted to provide rapid relief of breathlessness symptoms in patients with airway obstruction, improve quality of life, reduce the chances of re-obstruction due to tumor re-growth and associated medical costs and, most importantly, may prolong survival. The MTDS is a platform technology and has the potential to treat other cancers such esophageal, colon, bile duct and other cancers. The specific aims of this proposal include: Demonstrating the feasibility of developing prototype MTDS with slow, and fast drug and dye release profile, developing test methods to evaluate performance, and testing the effectiveness of the lead prototype MTDS in a mouse tumor model. The research methods are expected to result in (a) identifying the technological limitations and conditions that provide maximum drug and dye loading capacity with desired release profiles (b) identifying the sensitivity and accuracy of the test methods (c) identifying a therapeutically effective dose window in the mouse tumor model (d) Projecting product profile for clinical testing.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

4 SBIR/STTR records share this UEI (2006–2011). Reported award amounts total $599,999. Reported amounts are not federal obligations.

Phases: Phase I

Agencies: Department of Health and Human Services, National Science Foundation

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.